Digestive Health

Mirikizumab met both co-primary end points and all secondary end points at week 52, according to results presented at Digestive Disease Week in Washington DC.

There was no difference observed between adalimumab (Humira; AbbVie) and adalimumab-aacf (Idacio; Fresenius Kabi) for those who switched to the biosimilar.

This holistic approach to healing, grounded in harnessing the therapeutic properties of plants, serves as a bridge between centuries-old traditional wisdom and modern scientific practices.

Melatonin is linked to circadian rhythm, mitochondrial function, and neuroinflammation.

Dedicated clinical trials in IBD cohorts that scrutinized biosimilar use in real-world clinical practice have direct implications on decision making.

Investigators suggested that this difference is caused by a common medication for treatment-resistant schizophrenia.

However, increasing dietary niacin did not reduce risk of mortality from cardiovascular disease, the primary cause of death associated with nonalcoholic fatty liver disease.

Targeted use of ultraviolet light and sporicidal treatment can reduce disease transmission alongside existing interventions.

Researchers will continue to research how lantibiotic’s antimicrobial effects can be harnessed for good.

The vitamin improved lipid metabolism to slow the progression of the disease.

The designation offers support in developing potential new medicines, treatment, and diagnosis to prevent rare conditions, like EoE.

Patients who are immunocompromised generally had worse risk and severity of CDI.

According to the authors, identifying the degree of disagreement with physicians’ deprescribing recommendations can improve the communication among older adults and their physicians.

The effects of probiotic strains on both constipation and cognition among all individuals involved in a meta-analysis remains difficult to determine.

Social jet lag could create adverse health impacts that a 90-minute difference in the mid-point of sleep can improve.

Therapeutic drug monitoring is a growing and vital area for pharmacists to become involved in to increase patient success with inflammatory bowel disease remission.

As more becomes known about Crohn disease, treatment modalities have evolved with biologic monoclonal antibodies becoming a key part of guideline- and evidence-based medicine.

In clinical trials of patients with Crohn disease, upadacitinib demonstrated early and long-term symptom relief, as well a visible reduction of damage to the intestinal lining caused by excess inflammation.

The sleep hormone decreased intestinal homeostasis, which may augment inflammation that causes tissue and intestinal damage.

As patents expire, the development of biosimilars may increase, opening up new opportunities to compare efficacies of these drugs.

Similarities between the symptoms of Clostridioides difficile infection and Crohn disease may cause confusion for health care providers.

The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.

Different guidelines have notable differences between equivalency dosing of proton pump inhibitors (PPI), resulting in confusion and a lack of confidence between medical professionals recommending one PPI over another.

Purine metabolite xanthine, found in caffeinated beverages and food, affect cell differentiation, and new study results may lead to more knowledge about why diseases such as IBD develop.

Educate patients about the use of nonprescription products for digestive issues, and encourage them to seek further medical care when warrented.

Few Americans' diets meet the FDA's dietary guidelines; minerals and vitamins can pick up the slack to contribute to digestive health.

The popularity of intermittent fasting, or time-restricted eating patterns, may not help control weight as well as other dieting methods.

Products range from natural eye relief to sleep aid.

Analysis indicates that for individuals older than aged 40 years, the risk is cumulative and greatest 1 to 2 years after use.